Literature DB >> 14990756

Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease.

Edward C Lauterbach1, Alan Freeman, Robert L Vogel.   

Abstract

The authors investigated the prevalence of DIS-ascertained DSM-III psychiatric disorders occurring in 28 patients with dystonia and 28 patients with Parkinson's Disease (PD). In patients with dystonia, lifetime prevalences of major depression (25.0%), bipolar disorder (7.1%), atypical bipolar disorder (7.1%), social phobia (17.9%), and generalized anxiety disorder (25.0%) were significantly more common than in epidemiologic catchment area (ECA) study population controls (p < 0.005). Social phobia and generalized anxiety disorder preceded dystonia (primary), while bipolar disorder developed after dystonia onset (secondary). In PD patients, the lifetime prevalence of simple phobia (35.7%, p < 0.0001) and atypical depression (21.4%) were significantly more common. Parkinson's Disease was associated with primary simple phobia and secondary atypical depression. These findings are considered in light of previous results and in terms of the differences in pallidothalamic physiologies in dystonia and PD. These data suggest distinctive profiles of psychiatric disorders in dystonia and PD.

Entities:  

Mesh:

Year:  2004        PMID: 14990756     DOI: 10.1176/jnp.16.1.29

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  20 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne A Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

3.  Higher zinc concentrations in hair of Parkinson's disease are associated with psychotic complications and depression.

Authors:  Altair Brito Dos Santos; Marcos A Bezerra; Marcelo E Rocha; George E Barreto; Kristi A Kohlmeier
Journal:  J Neural Transm (Vienna)       Date:  2019-07-11       Impact factor: 3.575

Review 4.  Nonmotor manifestations of dystonia: a systematic review.

Authors:  Daniel J Kuyper; Veronica Parra; Shanae Aerts; Michael S Okun; Benzi M Kluger
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

Review 5.  Anxiety and medical disorders.

Authors:  Jacqueline E Muller; Liezl Koen; Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

6.  Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers.

Authors:  James A Bourgeois; Andreea L Seritan; E Melina Casillas; David Hessl; Andrea Schneider; Ying Yang; Inderjeet Kaur; Jennifer B Cogswell; Danh V Nguyen; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

Review 7.  Early Parkinson's disease and non-motor issues.

Authors:  K Ray Chaudhuri; Yogini Naidu
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 8.  Neuropsychiatric symptoms in Parkinson's disease.

Authors:  Dag Aarsland; Laura Marsh; Anette Schrag
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

9.  Increased c-fos expression in the central nucleus of the amygdala and enhancement of cued fear memory in Dyt1 DeltaGAG knock-in mice.

Authors:  Fumiaki Yokoi; Mai T Dang; Courtney A Miller; Andrea G Marshall; Susan L Campbell; J David Sweatt; Yuqing Li
Journal:  Neurosci Res       Date:  2009-07-18       Impact factor: 3.304

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.